← All trials
NCT04567251
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2021
- Primary completion
- Apr 30, 2022
- Completion date
- Apr 30, 2022
- First posted
- Sep 28, 2020
- Last posted
- Dec 14, 2020
- Enrollment
- 108
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Duke UniversityLead sponsor
- Duke UniversityOverall official - principal investigator
- AllerganCollaborator
- Varian Medical SystemsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.